TAG and 134 other organizations sent this letter to underscore the need for a swift response from UNITAID to hepatitis C virus (HCV) coinfection; delays will cost lives and impede scale-up when more effective and tolerable therapies are available.
HIV i-Base and Treatment Action Group (TAG) called on global and national leaders, research sponsors, and regulatory authorities to work together to make the best HIV, HCV, and TB drugs, diagnostics, and vaccines accessible as fast as possible, according to a report released today at the 7th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention in Kuala Lumpur, Malaysia.
Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development: Written by Polly Clayden, Simon Collins, Colleen Daniels, Mike Frick, Mark Harrington, Tim Horn, Richard Jefferys, Karyn Kaplan, Erica Lessem, and Tracy Swan
Health insurance co-payment (co-pay) programs and patient drug assistance programs (PAPs) are critical services for thousands of U.S. residents with HIV and/or viral hepatitis who face out-of-pocket expenses associated with their treatment. The Fair Pricing Coalition (FPC) has negotiated co-pay…
Gilead’s greed gives rise to a slew of advocacy priorities By Tracy Swan Activists are decrying Gilead’s refusal to continue codeveloping a winning HCV drug combination with Bristol-Myers Squibb (BMS), opting instead to focus on co-formulations of its own promising…
By Mark Harrington Now in its 20th year of publication, TAGline has long sought to inform its readers and TAG supporters of the myriad research and policy challenges we face as a community in the ongoing fight against HIV and…
Advancing Research, Securing Access: Now in its 20th year of publication, TAGline has long sought to inform its readers and TAG supporters of the myriad research and policy challenges we face as a community in the ongoing fight against HIV and two of its insidious comorbidities, viral hepatitis and tuberculosis. Many of these challenges are inextricably intertwined, as we highlight in this issue focusing on specific clinical research and treatment-access hurdles threatening progress for all three diseases.
April 2013 What predicts response to hepatitis C virus (HCV) treatment? Many things help predict the likelihood of being cured (called sustained virological response or SVR) by pegylated interferon (PEG-IFN) and ribavirin (RBV). Making sure to take all medications as…
February 14, 2013 – Today, on the occasion of Valentine's Day, Médecins du Monde and Treatment Action Group (TAG) are launching an action urging pharmaceutical giants Merck and Roche to drop their exorbitant prices for pegylated interferon, an effective hepatitis…
by Karyn Kaplan The current standard of care for HCV is pegylated interferon (PEG-IFN) and ribavirin. Yet in most countries, this treatment is unaffordable to all but the wealthiest people. In order to stimulate price reductions and increase access, Médecins…